Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.37 |
| ▸ | MEN1 | O00255 | 6/20 | 0.37 |
| ▸ | MAPT | P10636 | 8/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.35 |
| ▸ | PARL | Q9H300 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5653363 | 1.00 | CRHBP (0.39) | CRHBPGFERCRHR2KMT2AMEN1 | |
| SCHEMBL9891734 | 0.82 | CRHBP (0.43) | CRHBPGFERCRHR2KMT2AMEN1 | |
| SCHEMBL30912424 | 0.73 | KMT2A (0.46) | CRHBPGFERCRHR2KMT2AMEN1 | |
| SCHEMBL30912496 | 0.73 | KMT2A (0.46) | CRHBPGFERCRHR2KMT2AMEN1 | |
| SCHEMBL2570723 | 0.71 | MAPT (0.49) | CRHBPGFERCRHR2KMT2AMEN1 | |
| SCHEMBL2570725 | 0.71 | MAPT (0.49) | CRHBPGFERCRHR2KMT2AMEN1 | |
| SCHEMBL15400621 | 0.70 | CRHBP (0.38) | CRHBPGFERCRHR2KMT2AMEN1 | |
| SCHEMBL15400620 | 0.70 | CRHBP (0.38) | CRHBPGFERCRHR2KMT2AMEN1 | |
| SCHEMBL9893017 | 0.70 | KMT2A (0.46) | CRHBPGFERCRHR2KMT2AMEN1 | |
| SCHEMBL27959325 | 0.70 | CRHBP (0.43) | CRHBPGFERCRHR2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150099720-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-04-09 | — | — | US | claimed |
| US-20140005186-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-01-02 | — | — | US | claimed |
| US-9359285-B2 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150099720-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-04-09 | — | — | US | disclosed |
| US-8865918-B2 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140005186-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-01-02 | — | — | US | disclosed |
| US-8519158-B2 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-20070254875-A1 | Androgen Receptor Modulator Compounds and Methods | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2007-11-01 | — | — | US | disclosed |
| WO-2005090282-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099720-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | AR, SHBG, NR5A1 | CRHBP 599/4885GFER 2135/4885CRHR2 229/4885 |
| US-20140005186-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | AR, SHBG, NR5A1 | CRHBP 599/4885GFER 2135/4885CRHR2 229/4885 |
| US-20070254875-A1 | Androgen Receptor Modulator Compounds and Methods | AR, SHBG, NR5A1 | CRHBP 599/4885GFER 2135/4885CRHR2 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.